<DOC>
	<DOCNO>NCT00922129</DOCNO>
	<brief_summary>The purpose study evaluate role effectiveness conversion sirolimus versus CNI reduction renal transplant patient prostate cancer .</brief_summary>
	<brief_title>Effectiveness Conversion Sirolimus Versus Calcineurin Inhibitor ( CNI ) Reduction Renal Transplant Patients With Prostate Cancer</brief_title>
	<detailed_description>This study design support optimal use mTOR-inhibitor provide data safe effectiveness use sirolimus . This study take account effectiveness aspects malignancy-free survival cancer reduce overall exposure calcineurin inhibitor .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Male patient ≤ 50 year post renal transplant followup ; Biopsy confirm prostate cancer ; Stable renal function GFR ≥ 40 mL/min . Patients metastatic disease ; Uncontrolled hyperlipidemia ; Proteinuria &gt; 500 mg/day ; Biopsy evidence acute rejection within past 3 month ; Existence surgical medical condition , current transplant , opinion investigator might significantly alter absorption , distribution , metabolism excretion study medication ; Patients mental illness ; Inability cooperate communicate investigator unable complete self administer questionnaire .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Sirolimus</keyword>
	<keyword>Calcineurin inhibitor</keyword>
	<keyword>prostate cancer</keyword>
</DOC>